. •--

JAN 2 1 2009

## **Facsimile Cover Sheet**

To: Examiner Walter E. Webb

Company: United States Patent and Trademark Office

Phone: (571) 272-3553 Fax: (571) 273-8300

From: Linda Marchione

Company: LyondellBasell Industries

Phone: (610) 359-2416 Fax: (610) 359-2414

Date: January 20, 2009

Re: Application No. 10/552,574

Pages including this cover page: 9

Dear Examiner Webb:

This Office Action was sent to Customer Number 24114. Please note that this is not our patent application and it is not associated with our Customer Number 24114.

Please correct your records.

Thank you.

Regards,

Linda Marchione

If you experience difficulty receiving this transmission, please call Linda Marchione at (610) 359-2416.

CONFIDENTIAL

RECEIVED CENTRAL FAX CENTER

PAGE 2/8 * RCVD AT 1/20/2009 2:54:07 PM [Eastern Standard Time] * 5/R:USPTO-EFXRF-6/34 * DMIS:27:38:300 * CSID:6103592414 * DURATION (mm-ss):02-02 ** PAGE 2/8 * RCVD AT 1/20/2009 2:54:07 PM [Eastern Standard Time] * 5/R:USPTO-EFXRF-6/34 * DMIS:27:38:300 * CSID:6103592414 * DURATION (mm-ss):02-02 ** PAGE 2/8 ** RCVD AT 1/20/2009 2:54:07 PM [Eastern Standard Time] * 5/R:USPTO-EFXRF-6/34 ** DMIS:27:38:000 ** CSID:6103592414
may reduce any carned patent term adjustment. See 37 CFR 1.704(b).  NOTICE OF APPEAL
2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).  AMENDMENTS
The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because  (a) They raise new issues that would require further consideration and/or search (see NOTE below);  (b) They raise the issue of new matter (see NOTE below);
(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) They present additional claims without canceling a corresponding number of finally rejected claims.  NOTE: (See 37 CFR 1.116 and 41.33(a)).
4. The amendments are not in compliance with 37 CFR 1.121. See attached Notloe of Non-Compliant Amendment (PTOL-324).  5. Applicant's reply has overcome the following rejection(s):
6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
7. 🖾 For purposes of appeal, the proposed amendment(s): a) l T will not be entered, or b) 🕅 will be entered and an explanation of
70.00



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER HAR PATENTS PACKAGE ACCORDING 12313-1450

		***************************************	TING! WANTED HAVE AND COL	TATIONNES DOCKETNO.	CONFIRMATION NO.
	10/552,574	08/04/2006	James Davidson	010180.00043	4765
				EXAMINER	
				WEBB, WALTER E	
	NEWTOWNS	QUARE, PA 190/3		ART UNIT	PAPER NUMBER
			1612		
				MAIL DATE	DELIVERY MODE
				01/13/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

RECEIVED

JAN 2 0 2009

PATENT DEPARTMENT

PACE 3/8 \* RCVD AT 1/20/2009 2:54:07 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-6/54 \* DMIS:2738300 \* CSID:6103992414 \* DURATION (mm-ss):02-02

Continuation Sheet (PTO-303)

Application No. 10/552,574

Continuation of 11. does NOT place the application in condition for allowance because: Applicant continues to argue that the prior art compounds of Achard are not structurally similar to the instant compounds, and are not expected to have this same CB1 antagonistic activity. However, the rejection is over a combination of Adams and Achard, and both references teach treatment of the same CNS disorders such as anxiety and epilepsy. Given the similar structure of the compounds of Adams and Achard and their ability to treath the same CNS disorders, the artisan would have reasonably expected the compounds of Adams to also treat other CNS disorders taught in Achard such as bullimia. Applicant argues that the molecular target in Adams is the GABAa receptor and modulation of this receptor in not known in the art to be involved with the claimed disorders. However, this is untrue. For the purposes of rebutting applicant's statement, Rosmond et al. (International Journal of Obesity 2002) is cited. This references teaches that varients in the GABAa receptor subunit gene is associated with abdominal obesity. (See Abstract.) Abdominal obesity is caused by excess cortisol, which results when cortisol is not properly regulated through the binding of GABA to GABAa receptors. (See pg. 938, right column second paragraph.) Applicant's arguments are unpersuasive. The teachings of Adams and Archard provide a reasonable basis for treating disorders instantly claimed with the compound(s) of Adams.

PAGE 4/8 \* RCVD AT 1/20/2009 2:54:07 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-6/34 \* DNIS:2738300 \* CSID:6103592414 SO-SO:(ee-mm) NOITARUG \*

				Application/Co	ntrol No	Applicant(s)	Petent Under				
		Madian of Deforman	o Citod	10/552,574	Application/Control No. 10/552,574		Applicant(s)/Patent Under Reexamination DAVIDSON ET AL.				
		Notice of Reference	s Citea	Examiner		Art Unit					
				WALTER E. V	VEBB	1612	Page 1 of 1				
U.S. PATENT DOCUMENTS											
•		Document Number Country Code-Number-Kind Code	Date MM-YYYY		Name		Classification				
	Α	US-					<u> </u>				
	В	U\$-									
	С	us-			** ** -	-	<del></del>				
	D	US-		w							
	E	US-			***************************************						
П	F	US-									
	G	US-									
	Н	us-									
	+	US-									
	J	US-									
	к	US-									
	L	US-									
	м	US-									
			F(	OREIGN PATENT DOCUM	MENTS						
*		Document Number Country Code-Number-Kind Code	r Date Country Name		me	Classification					
	N					-	<u> </u>				
	0				, . <u></u>						
	P				(entr						
	a	-			**************************************		****				
	R										
	s				<del></del>						
	Т										
				NON-PATENT DOCUME	NTS						
*		Includ	le as applicable:	Author, Title Date, Publish	er, Edition or Volum	no, Portinent Pages)					
	U	Pormond at al. "Allolic variants in the CARAcolohof recenter publishing one (CARRAS) is associated with a high significant									
	V										
	8	N									
	×										
"A co	A copy of this reference is not being turnished with this Office action, (See MPEP § 707.05(a).)										

U.S. Patent and Trademerk Office PTO-892 (Rev. 01-2001)

Notice of References Cited

Part of Paper No. 20090109